Los Angeles Capital Management LLC purchased a new position in Surgery Partners, Inc. (NASDAQ:SGRY – Get Rating) in the fourth quarter, according to the company’s latest 13F filings with the U.S. Securities and Exchange Commission. purchased 9,191 shares of the company stock valued at approximately $256,000.
Other hedge funds have increased or decreased their stakes in the company recently. PNC Financial Services Group Inc. increased his position in Surgery Partners by 34.7% in the first quarter. PNC Financial Services Group Inc. now owns 1,195 shares of the company worth $66,000 after purchasing an additional 308 of his shares during the previous quarter. Allspring Global Investments Holdings LLC increased its stake in Surgery Partners by 139.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,379 shares of the company, valued at $32,000, after purchasing an additional 804 shares during this period. Signaturefd LLC won a new position in Surgery Partners in the third quarter worth approximately $43,000. Great West Life Assurance Co. Can won a new position in Surgery Partners in the third quarter worth approximately $44,000. Finally, Vontobel Holding Ltd. won a new position in Surgery Partners in the first quarter worth approximately $217,000.
insider trading
In related news, insider Bradley R. Owens sold 1,669 shares of Surgery Partners in a transaction on Monday, March 13th. The shares sold for an average of $30.10, giving him a total of $50,236.90. After the transaction, the insider now owns his 83,959 shares of the company, valued at approximately $2,527,165.90. The sale was disclosed in legal filings with the U.S. Securities and Exchange Commission, which can be accessed via this hyperlink. In related news, CEO Jason Eric Evans sold 10,300 shares of Surgery Partners in a transaction on Monday, March 13th. The shares were sold at an average price of $30.11 for a total of $310,133.00. After the transaction, the CEO now owns 426,554 shares in the company, valued at approximately $12,843,540.94. The sale was disclosed in legal filings with the U.S. Securities and Exchange Commission, which can be accessed via this hyperlink. Also, his insider, Bradley R. Owens, sold 1,669 shares of the company’s stock in a transaction on Monday, March 13. The shares sold for an average of $30.10, and the total transaction value he had was $50,236.90. After the transaction, the insider now owns his 83,959 shares of the company, valued at approximately $2,527,165.90. Please see here for the disclosure of this sale. Insiders sold 76,274 shares of company stock worth $2,530,979 last quarter. 3.30% of the shares are now owned by internal parties.
Surgery partner share price increase 1.4 %
Surgery Partners shares opened at $35.21 on Friday. The company has a market capitalization of $4.45 billion, a P/E ratio of -38.27 and a beta of 2.74. The company has a 50-day simple moving average of $34.75 and a 200-day simple moving average of $31.16. The company has a current ratio of 1.83, a quick ratio of 1.72 and a debt to equity ratio of 0.86. His one-year low at Surgery Partners, Inc. is $20.46 and his one-year high is $54.98.
Surgery Partners (NASDAQ:SGRY – Get Rating) last reported quarterly results on Wednesday, March 1. The company reported that his earnings per share for the quarter were $0.22, beating analyst consensus expectations of $0.16 for him by $0.06. The business generated $707.1 million in revenue for the quarter, compared to consensus expectations of $688.34 million. Surgery Partners’ net profit margin was negative 3.51% and return on equity was 0.59%. Sell-side analysts forecast his earnings per share for Surgery Partners, Inc. to be 0.34 for the current fiscal year.
Analyst sets new price target
A number of equity analysts have recently commented on the SGRY stock. JPMorgan Chase & Co. lowered its price target for Surgery Partners from $45.00 to $40.00 and set the company’s rating to “neutral” in its research notes on Thursday, March 2. Barclays lowered its price target on Surgery Partners shares from $69.00 to $56.00 and set the company’s rating to Overweight in its research notes on Wednesday, January 18th. StockNews.com upgraded Surgery Partners’ shares from a ‘sold’ rating to a ‘pending’ rating in a research note on Tuesday, May 2nd. Cantor Fitzgerald began reporting on the stake in Surgery Partners in a research note on Thursday, April 20th. They set an “overweight” rating and a company target price of $43.00 for him. Finally, Benchmark reissued a ‘buy’ rating and in a research note on Monday, March 6, he set a price target of $47.00 on Surgery Partners stock. Three Research his analysts rated the stock with a hold rating and six gave the company a buy rating. Based on MarketBeat.com data, the company’s current consensus rating is “moderate buy” with an average target price of $42.80.
Surgery partner company profile
(get rating)
Surgery Partners, Inc. is a healthcare services holding company engaged in providing surgical and related ancillary medical solutions to support patients and physicians. It operates through the following business segments: Surgical Facility Services, Auxiliary Services, and Optical Services.
read more
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.
Listen to this before considering a surgical partner.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified 5 stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Surgery Partners wasn’t on the list .
Surgery Partners currently holds a ‘moderate buy’ rating among analysts, although the highest rated analysts believe these five stocks are better buys.
See 5 stocks here
Elon Musk’s next move
When will we finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to find out when Elon Musk will finally allow these companies to IPO. Please Confirm.
Get This Free Report
